Episode 505: A Breakthrough in Cholesterol Care With an Oral PCSK9 Inhibitor

This week, Dr. Kahn discusses the FDA approval of the first oral PCSK9 inhibitor, Lipfendra (enclicitide), taken as a 20 mg daily tablet. In a study of nearly 3,000 patients with elevated LDL cholesterol despite treatment with statins and, in many cases, ezetimibe, LDL-C dropped by more than 50% while Lipoprotein(a) levels fell by 28%, with an excellent safety profile. The medication is expected to retail for approximately $315 per month and will be available in pharmacies soon. A larger outcomes trial evaluating its impact on heart attack and stroke rates is currently underway. Other topics include oatmeal for diabetes, avocados for cholesterol, ketogenic diets and cancer, serotonin and heart valve disease, air pollution and cardiovascular events, and the relationship between sweetened beverages, fruit juice, and high blood pressure. Dr. Kahn also mentions the air filtration system he uses at home and in his office, available at: airdoctorpro.com Finally, thanks to this week's sponsor, the Fresh Pressed Olive Oil Club. Learn more at getfreshDrKahn.com.